BRAF and melanoma: The only combination therapy that doesn’t target angiogenesis directly is given in BRAF-mutated advanced melanoma, i.e., a combination of Vemurafenib (a BRAF inhibitor), cobimetinib (a mitogen-activated extracellular kinase (MEK) inhibitor), and atezolizumab (Morante et al., 2022).